Clinical trials: Neurocognitive Disorders
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Alzheimer's Disease, Dementia
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
This study will evaluate acute symptomatic improvements in cognitive performance in healthy elderly participants with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00874939
- Testing
- MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Caring Light Project for Family Caregivers
Caring Light is designed to help caregivers of someone with Alzheimer's Disease and related dementia to cope with the difficulties related to caregiving, reduce stress, and improve quality of life.
- Trial name
- NCT04517877
- Testing
- Caring Response App, Traditional Educational/Resources Program
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Photozig, Inc.
Maximum Diagnostic Mass of [18Fluor]AZD4694
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress…
- Trial name
- NCT01325402
- Testing
- [18Fluor]AZD4694
- Where
- 2 sites in Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Disorientation, Cognitive Impairment
Evaluation of Safe Use of SECURIDRAP® SELFIA®
Interventional, multicenter, prospective and non-comparative clinical investigation carried out in 9 French establishments in order to assess the safety of the SÉCURIDRAP® SELFIA® bedding by mesasuring all the adverse events…
- Conditions
- Disorientation, Cognitive Impairment, Behavior Disorders
- Trial name
- SECURIDRAP (NCT05510401)
- Testing
- SECURIDRAP® SELFIA®
- Where
- 10 sites in France
- Volunteers
- 108 people
- Sponsor
- Groupe Mulliez-Flory
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer Disease
COGNIShunt® System for Alzheimer's Disease
This is a study of the effect on the progression of Alzheimer's Disease of a surgically implanted shunt (tube) to increase the flow of cerebrospinal fluid and improve the clearance of potential neurotoxins from the fluid bathing…
- Trial name
- NCT00056628
- Testing
- The COGNIShunt® System
- Volunteers
- 250 people
- Sponsor
- Eunoe
Mild Alzheimer Disease
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease
To evaluate the safety and efficacy of PM012 tablets for Alzheimer's disease, dose-finding study will be performed on phase 2b, and the established dose will be used for the non-inferiority phase 3 trial to evaluate the…
- Trial name
- PM012-2b (NCT05811000)
- Testing
- PM012, Donepezil
- Where
- South Korea
- Volunteers
- 312 people
- Sponsor
- Mediforum Ltd., Co.
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer Disease, Early Onset
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase 3 study comparing LIPUS-Brain transcranial low-intensity pulsed-wave ultrasound device to placebo in patients with Early Alzheimer's Disease.
- Trial name
- NCT05983575
- Testing
- LIPUS-Brain
- Where
- 19 sites in Japan
- Volunteers
- 220 people
- Sponsor
- Sound Wave Innovation CO., LTD.
Alzheimer's Disease
A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
A study to assess the steady-state bioequivalence of once-weekly Corplex™ Donepezil 10 mg Transdermal Delivery System (TDS) compared to daily administration of Aricept®
- Trial name
- NCT03259958
- Testing
- Donepezil TDS, Aricept
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Schizophrenia, Cognition
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.
- Trial name
- NCT00654706
- Testing
- Sertindole, Quetiapine
- Where
- 26 sites in United States
- Volunteers
- 264 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00151333
- Testing
- SRA-333
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease, Late Onset
Tdap and Biomarkers of Alzheimer's Disease
Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia.
- Trial name
- NCT05183516
- Testing
- tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
Huntington Disease
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their…
- Trial name
- NCT06667414
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 574 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants
The purpose of this study is to determine pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and the relative-bioavailability (the extent to which a drug or other substance becomes…
- Trial name
- NCT02260700
- Testing
- JNJ-54861911 (Treatment A), JNJ-54861911 (Treatment B), JNJ-54861911 (Treatment C)
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease, Dementia
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.
- Conditions
- Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- ATC-P001 (NCT06088121)
- Testing
- ATNC MDD-V1 (Real TMS + Real Cog), ATNC BN-V1, ATNC BN-V2
- Where
- 11 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Advanced Technology & Communications
Alzheimer's Disease
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.
- Trial name
- NCT00857649
- Testing
- Memantine
- Where
- 23 sites in Canada
- Volunteers
- 369 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT02220738
- Testing
- ABT-957
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- AbbVie